HomeCompareCFX vs ARCC

CFX vs ARCC: Dividend Comparison 2026

CFX yields 5.12% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CFX wins by $3.5K in total portfolio value· pulled ahead in Year 3
10 years
CFX
CFX
● Live price
5.12%
Share price
$39.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$710.37
Full CFX calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — CFX vs ARCC

📍 CFX pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCFXARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CFX + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CFX pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CFX
Annual income on $10K today (after 15% tax)
$435.23/yr
After 10yr DRIP, annual income (after tax)
$603.81/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, CFX beats the other by $602.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CFX + ARCC for your $10,000?

CFX: 50%ARCC: 50%
100% ARCC50/50100% CFX
Portfolio after 10yr
$26.3K
Annual income
$355.76/yr
Blended yield
1.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

CFX
Analyst Ratings
14
Buy
12
Hold
2
Sell
Consensus: Buy
Price Target
$51.00
+30.6% upside vs current
Range: $45.00 — $57.00
Altman Z
-0.2
Piotroski
4/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CFX buys
0
ARCC buys
0
No recent congressional trades found for CFX or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCFXARCC
Forward yield5.12%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$28.0K$24.5K
Annual income after 10y$710.37$1.16
Total dividends collected$6.2K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$51.00$21.88

Year-by-year: CFX vs ARCC ($10,000, DRIP)

YearCFX PortfolioCFX Income/yrARCC PortfolioARCC Income/yrGap
1$11,212$512.03$11,381$541.15$169.00ARCC
2$12,533$536.54$12,621$284.08$88.00ARCC
3← crossover$13,971$560.53$13,827$145.31+$144.00CFX
4$15,533$583.96$15,062$73.43+$471.00CFX
5$17,227$606.77$16,364$36.89+$863.00CFX
6$19,062$628.92$17,757$18.49+$1.3KCFX
7$21,047$650.38$19,258$9.25+$1.8KCFX
8$23,191$671.12$20,880$4.63+$2.3KCFX
9$25,506$691.12$22,636$2.32+$2.9KCFX
10$28,002$710.37$24,539$1.16+$3.5KCFX

CFX vs ARCC: Complete Analysis 2026

CFXStock

Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment for use in cutting, joining, and automated welding, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the general industry, construction, infrastructure, transportation, energy, renewable energy, and medical and life sciences markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. Colfax Corporation was founded in 1860 and is headquartered in Wilmington, Delaware.

Full CFX Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this CFX vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CFX vs SCHDCFX vs JEPICFX vs OCFX vs KOCFX vs MAINCFX vs HTGCCFX vs GBDCCFX vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.